Tag: division
IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
 |
SM17 is the world's first monoclonal antibodies targeting IL17BR co-developed by SinoMab and LifeArc (a medical research charity based in the United Kingdom). SM17 has a wide range of indications, including indications with large market volumes such as asthma and diseases with high mortality rates such as idiopathic pulmonary fibrosis. Comparing to other products on the market, SM17 enjoys differentiation advantages. With the preclinical data and unique mechanism of action of SM17, Company believes that SM17 potentially has a broader and more beneficial effect on asthma treatment than other approved biologics.
In the global market, the number of asthma patients is gradually increasing and is expected to reach 247.5 million by 2023 and further increase to 267.7 million by 2030. The number of asthma patients in the PRC is increasing at a greater pace than the global rate and is forecasted to reach 25.6 million by 2023 and further increase to 27.8 million by 2030. In terms of market size, the global asthma market is projected to reach US$25.1 billion by 2023 and US$34.6 billion by 2030. However, the asthma market in the PRC is expected to reach RMB36.4 billion by 2023 and RMB65.0 billion by 2030. In terms of treatment options, traditional asthma treatment is based on inhaled corticosteroid, but they are prone to serious adverse effects, especially in adolescents. Drug resistance can also develop if used for a long time. The introduction of SM17 is expected to provide a better treatment option in terms of the balance of efficacy and safety.
Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "following the acceptance of the IND application for SN1011 for the treatment of multiple sclerosis by the NMPA, the acceptance of the SM17 IND application by the FDA fully demonstrates the efficient execution of the Company's new drug R&D program. There is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. We are therefore confident in the enormous prospects of SM17's clinical development. Our core products, including SM03, SN1011 and SM17, is making progress on the clinical R&D smoothly, driving the Company moving steadily towards commercialization. In the future, we will accelerate our projects implementation to bring benefits to patients and create value for shareholders through innovation."
About SM17
SM17 is known to be the world's first humanized, IgG4-k monoclonal antibody for new drug development, which targets IL-17RB. And IL-17RB is a type-I single transmembrane glycoprotein belonging to IL-17 receptor family. The binding of SM17 to IL-17RB could suppress Th2 immune responses induced by a category of cytokines called "alarmin", which has shown to be implicated in the pathogenesis of allergic disease and airway viral responses. Alternative approach targeting upstream mediators of the Th2 inflammatory cascade, such as "alarmins", is expected to have a broader effect on airway inflammation and to provide more effective asthma control than currently available therapies, and products with similar mechanism of action as SM17 have been approved by FDA.
About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases
Bintai Kinden Corporation Berhad Emerges as Substantial Shareholder in Malaysian Genomics Resource Centre Berhad
 |
Bintai Kinden now has an effective shareholding of 5.03% stake in MGRC, following the acquisition of 6.25 million shares by Bintai Trading Sdn. Bhd., a wholly-owned subsidiary of Bintai Kinden, on 17 February 2022.
Following the acquisition, Encik Noor Azri bin Dato' Sri Noor Azerai ("Azri Azerai"), who was redesignated as an Executive Director of MGRC effective from 16 February 2022, will oversee the business development, human resources and finance functions of the Group. Azri Azerai has relinquished his role as Deputy Chief Executive Officer ("CEO") of Bintai Kinden after taking up the new role in MGRC, but will remain on the Board of Bintai Kinden as an Executive Director.
Azri Azerai, who was appointed to Bintai Kinden's Board in July 2021 as an Executive Director, and subsequently redesignated as the Deputy CEO, has successfully turned Bintai Kinden's earnings black since the first quarter of FY2022.
Speaking on his new role in MGRC, Azri Azerai said, "There are synergies in both companies that we intend to harness as Bintai Kinden diversified into the healthcare sector through the acquisition of Johnson Medical International Sdn. Bhd. ("JMI") in November 2021. We see plenty of opportunities that MGRC and Bintai Kinden can jointly enter into and leverage each other's strengths."
JMI specialises in medical facility development and construction projects where it provides medical engineering solutions such as operating theatres, critical care units and medical gas delivery systems. JMI is also a trader of medical equipment and supplies.
"We want both MGRC and Bintai Kinden to reap the benefits of working together. As I sit on the Boards of both companies, we will have better coordination and focus on where both companies can seek opportunities to grow as there is great potential for both."
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comMalaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, is pleased to announce the entry of a new substantial shareholder, Bintai Kinden Corporation Berhad ("Bintai Kinden"), a specialist in mechanical and electrical engineering services to the construction sector, in the Group.
Meta Says Full-body Tracking Probably Not Viable with Inside-out Headsets
The post Meta Says Full-body Tracking Probably Not Viable with Inside-out Headsets appeared first on Road to VR.
MicroPets Announced a Massive Overhaul to Their Rewards System
Washington, USA, Feb 16, 2022 - (ACN Newswire) - MicroPets, one of the most popular crypto projects on Binance Smart Chain with over 68,000 holders, has announced a massive overhaul to their rewards system. Although the changes just rolled out, MicroPets has already experienced a 100%+ increase in their price within a short period.
Rewards Changes
Like nearly every NFT staking project out there, MicroPets rewarded its native asset ($PETS). Since inception the team had given out an estimated $10.5MM in rewards–That's just three months! Despite the team hitting an all time high of $207 million, the selling pressure from rewards was a constant drain on the price.
The new rewards changes are a game changer and have been called genius by members within their own community. The team has dramatically limited rewards in $PETS tokens and instead gone with a completely different approach that combines NFT burning with BNB rewards.
The MicroPets team created two distinct pools: Unevolved and evolved. Investors who choose to receive $PETS rewards receive a tightly controlled quantity on a monthly basis. However, with the evolved pool, users receive BNB rewards in addition to the ability to buy $PETS tokens with BNB completely tax free. The result is a green wall that enables investors to dollar cost average their BNB rewards with a 0% buy tax while helping pump the chart at the same time.
Evolution
Knowing the NFT supply was high, the team incentivizes users to burn an NFT to begin the evolution process. Pairing an NFT with one of equal or higher rarity, the user burns one of the two and the NFT enters a 14 days incubation period. After, the user collects the Evolved NFT, which then enters the BNB staking pool.
The result? A reduction in NFT supply, less reward demand due to the incubation period, and a great pump, especially when you consider the team has put 800 BNB in the Evolution pool for the first 30 days. As of this writing, the reinvestment rate of BNB rewards is 85%, which is an incredible metric.
Data-Driven Decisions
The team has also brought on another key role that will support them in analyzing their blockchain data, ensuring live statistics on everything from rewards and reinvestment rates to pet prices, in addition to all major financial decisions. Such practice is a rare sight in the world of Decentralized Finance (DeFi), yet puts MicroPets in a class of its own. This level of transparency and insights is simply very very uncommon.
In fact, the team plans to use these key metrics to reward the right actions regarding the reward systems, ensuring a 30 days review with the community with performance goals.
P2E Innovation
MicroPets Runner is due out this quarter and is developed by a renowned app development firm. Recognizing that nearly every P2E game funds its own demise with its rewards systems, the MicroPets team has opted for an approach not yet seen in the space. Leveraging P2E as a marketing funnel, the team will draw in new users with free pets while leading them through the complete buying process as they work to acquire their first paid MicroPet.
How's this unique? First, the team will have a shop that's refreshed every 30 days that's powered by smart contracts. The shop will have 3D NFT's among other items players can claim in addition to a raffle ticket type system that enables smaller investors to still have fun and potentially earn as well!
The team will combine the best aspects of both Web 2.0 and Web 3.0, creating a rewards system that doesn't lead to excessive selling pressure while acting as a monthly draw for players to check out the refreshed shop!
Metaverse Expansion
The MicroPets team will be building its own metaverse expansion, named Petropolis, and is already working on telling the story of that vision using award-winning animation studio.
In Petropolis, MicroPets investors will be able to leverage their 3D NFT portfolio and land assets within a community-driven ecosystem and economy, all powered by the Petropolis token. Planned are six different land types, each with their own unique city, gathering & crafting resources, and more!
Upcoming Exchange Listings
Coinciding with the major upcoming releases for the MicroPets project and their upcoming P2E game are additional exchange listings. In fact, the MicroPets team has found a key partner that's guiding them on an "exchange blitz" that's designed to consistently move the project up the various exchange tiers, further driving visibility and awareness amongst several key markets, such as China.
Conclusion
The MicroPets team is poised for great success considering the recent changes to the rewards systems. The chart and resulting price action has spoken for itself thus far alongside the enthusiasm from the community. With everything else the team at MicroPets is working on, the future is bright and ripe with opportunity.
About MicroPets
MicroPets has taken the hottest memes in the crypto space, from Doge to Floki, and transformed them into loveable 3D NFT's. Users purchase MicroPets tokens on PancakeSwap, visit their custom-built dApp and then purchase a crate. Inside of the crate is a random 3D NFT, each with their own unique rarity and staking multiplier. The rarer the NFT the better the rewards. The team also has an upcoming Play-To-Earn (P2E) game in development by a renowned app development company, set for release this quarter. Thus far, the team has sold tens of thousands of 3D NFT's.
Social Links
Telegram: https://t.me/micropets
Twitter: https://twitter.com/micropetsbsc
Instagram: https://www.instagram.com/micropets.bsc/
Media Contact
Brand: MicroPets
Contact: Matthew Johnson, PR Director
Email: marketing@micropets.io
Website: https://www.micropets.io
SOURCE: MicroPets
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com
Latest Intelligence
